Interestingly, deficiency of CD73 in either hematopoietic or non-hematopoietic cells was reported to be sufficient to invigorate antitumor immunity [14,15], suggesting that the overall expression level of functional CD73 from both tumor cells and immune cells in the TME is a key factor determining the consequence of tumor growth or eradication. This evidence concerns the gene NT5E and neoplasm.